Original language | English |
---|---|
Article number | 152174 |
Journal | Comprehensive Psychiatry |
Volume | 100 |
DOIs | |
State | Published - Jul 2020 |
Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Comprehensive Psychiatry, Vol. 100, 152174, 07.2020.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - How to manage obsessive-compulsive disorder (OCD) under COVID-19
T2 - A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology
AU - Fineberg, N. A.
AU - Van Ameringen, M.
AU - Drummond, L.
AU - Hollander, E.
AU - Stein, D. J.
AU - Geller, D.
AU - Walitza, S.
AU - Pallanti, S.
AU - Pellegrini, L.
AU - Zohar, J.
AU - Rodriguez, C. I.
AU - Menchon, J. M.
AU - Morgado, P.
AU - Mpavaenda, D.
AU - Fontenelle, L. F.
AU - Feusner, J. D.
AU - Grassi, G.
AU - Lochner, C.
AU - Veltman, D. J.
AU - Sireau, N.
AU - Carmi, L.
AU - Adam, D.
AU - Nicolini, H.
AU - Dell'Osso, B.
N1 - Funding Information: LFF was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; grant # 302526/2018-8 , Rio de Janeiro, RJ, Brazil), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ; grant # CNE E-26/203.052/2017 , Rio de Janeiro, RJ, Brazil), the David Winston Turner Endowment Fund (Melbourne, VIC, Australia), and intramural grants from D'Or Institute for Research and Education (IDOR, Rio de Janeiro, RJ, Brazil). Funding Information: CIR has served as a consultant for Allergan, BlackThorn Therapeutics, Rugen Therapeutics, and Epiodyne, receives research grant support from Biohaven Inc. , and a stipend from APA Publishing for her role as Deputy Editor at The American Journal of Psychiatry. Funding Information: SP declares funding from the National Institute of Mental Health , USA; R21 NCTID NCT03669315 . Funding Information: The authors wish to acknowledge the International College of Obsessive Compulsive Spectrum Disorders ( www.ICOCS.org ), the European College of Neuropsychopharmacology (ECNP) Obsessive-Compulsive and Related Disorders Research Network (OCRN) and the COST Action CA16207 “European Network for Problematic Usage of the Internet”, supported by COST (European Cooperation in Science and Technology) ( www.cost.eu ), who have contributed, through providing networking opportunities, to the development of this guideline. Funding Information: JZ received grants and research support from Lundbeck , Servier , Brainsway , Pfizer & the DOD , honoraria and consultation fees from Lundbeck, Roche, Lilly, Servier, Pfizer.
PY - 2020/7
Y1 - 2020/7
UR - http://www.scopus.com/inward/record.url?scp=85085592954&partnerID=8YFLogxK
U2 - 10.1016/j.comppsych.2020.152174
DO - 10.1016/j.comppsych.2020.152174
M3 - Article
C2 - 32388123
AN - SCOPUS:85085592954
SN - 0010-440X
VL - 100
JO - Comprehensive Psychiatry
JF - Comprehensive Psychiatry
M1 - 152174
ER -